Skip to main content
. 2011 Mar 16;36(7):1319–1331. doi: 10.1038/npp.2011.8

Figure 7.

Figure 7

Effect of serotonin 1A receptor (5-HT1A-R) antagonism on behavioral enhancement seen after adolescent nicotine pretreatment. Adolescent animals received daily infusions of WAY 100 635 (N-{2-[4-(2-methoxyphenyl)-1-piperazinyl] ethyl}-N-(2-pyridinyl)cyclohexanecarboxamide) (0, 40, or 400 μg/kg, intravenous) in combination with nicotine pretreatment. WAY blocked the nicotine pretreatment effect on cocaine 1 (0.5 mg/kg/inf; a) intake and acquisition on day 1 and quinpirole-induced locomotion (0.4 mg/kg, intraperitoneal; b). ++p=0.001 vs saline. ###p<0.0001, ##p⩽0.001 vs nicotine. Administration of WAY had no effect on nicotine enhancement of penile erection in response to quinpirole (c). ***p<0.0001, *p<0.5 vehicle; ++p<0.001vs saline/quin (0.4); +p<0.05 vs saline+WAY (400). Cocaine: n=8–12 per group and quinpirole: n=4–8 per group.